Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: Functional and morphological evaluation

European Radiology

Volumn 23, Issue 3, 2013, Pages 805-815

  Guibal, Aymeric ^a,c   Lefort, Thibaud ^a   Chardon, Laurence ^a   Benslama, Noura ^a   Mulé, Sébastien ^b   Pilleul, Franck ^a   Lombard Bohas, Catherine ^a   Bridal, Lori ^c   Chayvialle, Jean Alain ^a   Lucidarme, Olivier ^c,d   Denys, Alban ^e   Walter, Thomas ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UPMC Univ Paris 06   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Contrast enhanced ultrasound; Doxorubicin drug eluting beads (DEB); Perfusion imaging; Transarterial chemoembolization; Tumour vitality index

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHROMOGRANIN A; DOXORUBICIN; IODIXANOL; SONOVUE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL ARTICLE; CONTRAST ENHANCED ULTRASOUND; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEVASCULARIZATION; DRUG EFFICACY; DRUG ELUTING BEAD; ECHOGRAPH; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; MICROBUBBLE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SUSTAINED RELEASE PREPARATION; TUMOR BLOOD FLOW; TUMOR VOLUME;

EID: 84878562000     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2646-4     Document Type: Article

References (39)

1. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE (2009) Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 72:517-528
2. Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G (2012) New treatment strategies in advanced neuroendocrine tumours. Dig Liver Dis 44:95-105
3. Dominguez S, Denys A, Madeira I et al (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12:151-157
4. Jordan O, Denys A, De Baere T, Boulens N, Doelker E (2010) Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 21:1084-1090
5. Lee KH, Liapi EA, Cornell C et al (2010) Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 33:576-582
6. Ohta S, Nitta N, Sonoda A et al (2009) Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits. Eur J Radiol 72:534-540
7. Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468-476
8. Namur J, Wassef M, Millot JM, Lewis AL, Manfait M, Laurent A (2011) Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J Vasc Interv Radiol 21:259-267
9. Malagari K, Alexopoulou E, Chatzimichail K et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 33:512-519
10. Lewis AL, Gonzalez MV, Leppard SW et al (2007) Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 18:1691-1699
11. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A (2010) Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21:327-332
12. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 101:476-480
13. de Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19:855-861
14. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
15. Forner A, Ayuso C, Varela M et al (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115:616-623
16. Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474-481
17. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 35:421-430
18. Memon K, Kulik L, Lewandowski RJ et al (2011) Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141:526-535, 535 e521-522
19. Rosen MA, Schnall MD (2007) Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 13:770s-776s
20. Miles KA (2003) Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 76:S36-S42
21. Padhani A (2006) PET imaging of tumour hypoxia. Cancer Imaging 6:S117-S121
22. Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757-762
23. Bouvier A, Ozenne V, Aube C et al (2011) Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 21:1719-1726
24. Malagari K, Pomoni M, Kelekis A et al (2009) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541-551
25. Zachary JF, Blue JP, Miller RJ, O'Brien WD Jr (2006) Vascular lesions and s-thrombomodulin concentrations from auricular arteries of rabbits infused with microbubble contrast agent and exposed to pulsed ultrasound. Ultrasound Med Biol 32:1781-1791
26. Guibal A, Taillade L, Mule S et al (2011) Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology 254:420-429
27. Lefort T, Pilleul F, Mule S et al (2012) Correlation and agreement between contrast-enhanced ultrasonography and perfusion computed tomography for assessment of liver metastases from endocrine tumors: normalization enhances correlation. Ultrasound Med Biol 38:953-961
28. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S (1998) Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 97:473-483
29. Krix M, Plathow C, Essig M et al (2005) Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound-initial results. Eur Radiol 15:677-684
30. Riaz A, Miller FH, Kulik LM et al (2010) Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303:1062-1069
31. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
32. Guiu B, Deschamps F, Aho S et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56:609-617
33. Moschouris H, Malagari K, Kornezos I, Papadaki MG, Gkoutzios P, Matsaidonis D (2010) Unenhanced and contrast-enhanced ultrasonography during hepatic transarterial embolization and chemoembolization with drug-eluting beads. Cardiovasc Intervent Radiol 33:1215-1222
34. Riaz A, Memon K, Miller FH et al (2011) Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 54:695-704
35. Krix M, Plathow C, Kiessling F et al (2004) Quantification of perfusion of liver tissue and metastases using a multivessel model for replenishment kinetics of ultrasound contrast agents. Ultrasound Med Biol 30:1355-1363
36. Browder T, Butterfield CE, Kraling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886
37. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z (2006) Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41:516-521
38. Liao XF, Yi JL, Li XR, Deng W, Yang ZF, Tian G (2004) Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 10:1885-1889
39. Feingold S, Gessner R, Guracar IM, Dayton PA (2010) Quantitative volumetric perfusion mapping of the microvasculature using contrast ultrasound. Invest Radiol 45:669-674